



15 April 2024

Upgraded FY24 earnings guidance

Blis Technologies Limited (NZX:BLT) advises that the draft full year financial results for the 12 months to 31 March 2024 have exceeded previous guidance due to favourable timing of several major customer orders, increased sales across our B2B channels and an underspend in some planned R&D expenditure for this year.

Our latest guidance for the year ended 31 March 2024 is for revenue of \$11.5m and EBITDA of \$0.8m subject to completion of the annual financial audit.

This is an increase on the previous guidance provided on 23rd February 2024 of revenue of around \$11.0m and EBITDA of breakeven to \$0.3m.

Blis Technologies' annual report and financial statements are expected to be released in late May.

Ends

For further information, please contact:

Scott Johnson
CEO
+64 021 488 831

About Blis Technologies Ltd

Delivering proven health benefits through evidence-based, advanced probiotics

Blis Technologies is an NZX-listed manufacturer of advanced probiotic strains that go beyond the gut. Combining innovation with evidence-based research and the highest quality production controls enables the delivery of probiotic solutions for specific health targets including throat health, halitosis (bad breath), immune support, teeth and gum health and skin health. BLIS® products are sold throughout New Zealand and in Asia, Europe and the USA. More information about Blis Technologies Ltd can be found at www.blis.co.nz.

Website: www.blis.co.nz
Instagram: @blisprobiotics #blisk12 #blism18 #blisq24
Facebook: @BLISProbiotics